Biotech Iproteos – co-founded by IRB Barcelona and based at the Parc Científic de Barcelona– has closed a round
The annual award recognizes individuals across the world who have made decisive contributions to foster endeavours of cultural, scientific or human significance.
Miquel A. Pericàs was born in Palma de Mallorca (Spain) in 1951. He studied Chemical Engineering (Institut Químic de Sarrià) and obtained his PhD degree (University of Barcelona) in 1979.
In the "II Foro Universitario de Unidad Editorial", held in Madrid, Joan Guinovart explained what, in his opinion, are the basic requirements to make progress in technology transfer in Spain.
La Voz de Galicia
In its supplement directed at schools, La Voz de Galicia published an article on the usefulness of the fly Drosophila melanogaster for biomedical research.
The article explains scientific breakthroughs made thanks to this fly and, among other examples, mentions the most recent study published by IRB Barcelona.
Researchers at IRB Barcelona and ICREA professors Raúl Méndez, Salvador Aznar Benitah and Eduard Batlle have co-headed the B·Debate. At the end of the event, they spoke to Gaceta Médica about the advances made in cancer epigenetics.
«Our study highlights the complexity of p38 functions, both in cancer and in the maintenance of normal tissues. It shows why an inhibitor of this molecule could effectively have undesirable side effects. But these do not exclude it from being a target against cancer.»
More on this news here.
Felice Alessio Bava
former PhD student in the Translational Control of Cell Cycle and Differentiation Lab
«We suspected that CPEB1, a protein involved in regulating mRNA translation in the cytoplasm, might also be active in the nucleus and play a role in controlling pre-mRNA processing. We discovered that it affects the alternative generation in the mature mRNA of the 3'-UTR, regions where most of the elements regulating translation in time and space are located.»
More info about this news here.
«Controlling a biological process from outside is the future of chemistry and opens up promising roads for advancements in pharmacological research.»
More info on this news here.
«98% of the potential therapeutic molecules against diseases of the central nervous system cannot cross the blood-brain barrier. We develop peptides with the capacity to open the doors of the barrier and act as shuttles when attached to a therapeutic molecule.»
Quick facts about IRB
IRB Barcelona has been awarded the "HR Excellence in Research" logo. This recognition reflects the commitment of the Institute to continuously improving its human resources policies in line with the European Charter for Researchers and the Code of Conduct for the Recruitment of Researchers. The award confirms the efforts of the Institute to ensure fair and transparent recruitment and appraisal procedures. Click here for more information.
IRB Barcelona is home to nearly 450 research, technical and support staff from 35 countries who share the common goal of contributing to the advancement of the biomedical sciences through investigator–driven research, and improving quality of life by applying advances in this field.
The convergence of biology, chemistry, and structural and computational biology is unique at IRB Barcelona and opens a strategic window to gain insight into basic molecular processes in health and disease.
Research is conducted by 23 groups organized into 5 interdisciplinary programmes. Each programme includes a diverse faculty of researchers with overlapping scientific interests. The research areas have been structured to be highly interactive, fostering multidisciplinarity by combining modern molecular biology, classical genetics, biochemistry, structural biology, bioinformatics, systems biology, advanced microscopy, and genomic and proteomic approaches.